Pioneer factors: Directing transcriptional regulators within the chromatin environment

Trends in Genetics

Volumn 27, Issue 11, 2011, Pages 465-474

  Magnani, Luca ^a   Eeckhoute, Jérôme ^b,c   Lupien, Mathieu ^a  

^a DARTMOUTH MEDICAL SCHOOL   (United States)

^b UNIV LILLE   (France)

^c INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GENETICS; CHROMATIN; DRUG TARGETING; EPIGENETICS; FEEDBACK SYSTEM; GENE MUTATION; GENOME; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROGNOSIS; REVIEW; TRANSCRIPTION REGULATION;

ANIMALS; CHROMATIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; GENE EXPRESSION REGULATION; HUMANS; MODELS, BIOLOGICAL; PROTEIN BINDING; PROTEIN TRANSPORT; TIME FACTORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 80054084614     PISSN: 01689525     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tig.2011.07.002     Document Type: Review

References (107)

1. Bushey A.M., et al. Chromatin insulators: regulatory mechanisms and epigenetic inheritance. Mol. Cell 2008, 32:1-9.
2. Chen Z., et al. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO J. 2011, 30:2405-2419.
3. Levine M. Transcriptional enhancers in animal development and evolution. Curr. Biol. 2010, 20:R754-R763.
4. Bulger M., Groudine M. Functional and mechanistic diversity of distal transcription enhancers. Cell 2011, 144:327-339.
5. Farnham P.J. Insights from genomic profiling of transcription factors. Nat. Rev. Genet. 2009, 10:605-616.
6. Graf T., Enver T. Forcing cells to change lineages. Nature 2009, 462:587-594.
7. Pan Y.P., et al. Mechanisms of transcription factor selectivity. Trends Genet. 2010, 26:75-83.
8. Fussner E., et al. Living without 30nm chromatin fibers. Trends Biochem. Sci. 2011, 36:1-6.
9. Bai L., Morozov A.V. Gene regulation by nucleosome positioning. Trends Genet. 2010, 26:476-483.
10. Laganiere J., et al. Location analysis of estrogen receptor alpha target promoters reveals that FOXA1 defines a domain of the estrogen response. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:11651-11656.
11. Bossard P., Zaret K.S. Repressive and restrictive mesodermal interactions with gut endoderm: possible relation to Meckel's Diverticulum. Development 2000, 127:4915-4923.
12. Cirillo L.A., et al. Binding of the winged-helix transcription factor HNF3 to a linker histone site on the nucleosome. EMBO J. 1998, 17:244-254.
13. Gualdi R., et al. Hepatic specification of the gut endoderm in vitro: cell signaling and transcriptional control. Genes Dev. 1996, 10:1670-1682.
14. Xu J., et al. Transcriptional competence and the active marking of tissue-specific enhancers by defined transcription factors in embryonic and induced pluripotent stem cells. Genes Dev. 2009, 23:2824-2838.
15. Carroll J.S., et al. Chromosome-wide mapping of estrogen receptor binding reveals long-range regulation requiring the forkhead protein FoxA1. Cell 2005, 122:33-43.
16. Bossard P., Zaret K.S. GATA transcription factors as potentiators of gut endoderm differentiation. Development 1998, 125:4909-4917.
17. Lupien M., Brown M. Cistromics of hormone-dependent cancer. Endocr. Relat. Cancer 2009, 16:381-389.
18. Heintzman N.D., et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009, 459:108-112.
19. Lupien M., et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008, 132:958-970.
20. Heinz S., et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol. Cell 2010, 38:576-589.
21. Odom D.T., et al. Tissue-specific transcriptional regulation has diverged significantly between human and mouse. Nat. Genet. 2007, 39:730-732.
22. Schmidt D., et al. Five-vertebrate ChIP-seq reveals the evolutionary dynamics of transcription factor binding. Science 2010, 328:1036-1040.
23. Birney E., et al. Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature 2007, 447:799-816.
24. Koch C.M., et al. The landscape of histone modifications across 1% of the human genome in five human cell lines. Genome Res. 2007, 17:691-707.
25. Heintzman N.D., et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat. Genet. 2007, 39:311-318.
26. Aday A.W., et al. Identification of cis regulatory features in the embryonic zebrafish genome through large-scale profiling of H3K4me1 and H3K4me3 binding sites. Dev. Biol. 2011, 10.1016/J.YDBIO.2011.03.007.
27. Rada-Iglesias A., et al. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011, 470:279-283.
28. Creyghton M.P., et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:21931-21936.
29. Ghisletti S., et al. Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity 2010, 32:317-328.
30. Feng R., et al. PUA and C/EBP alpha/beta convert fibroblasts into macrophage-like cells. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:6057-6062.
31. Serandour A.A., et al. Epigenetic switch involved in activation of pioneer factor FOXA1-dependent enhancers. Genome Res. 2011, 21:555-565.
32. Taube J.H., et al. Foxa1 functions as a pioneer transcription factor at transposable elements to activate AFP during differentiation of embryonic stem cells. J. Biol. Chem. 2010, 285:16135-16144.
33. Xu J., et al. Pioneer factor interactions and unmethylated CpG dinucleotides mark silent tissue-specific enhancers in embryonic stem cells. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:12377-12382.
34. Cirillo L.A., et al. Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. Mol. Cell 2002, 9:279-289.
35. Sekiya T., et al. Nucleosome-binding affinity as a primary determinant of the nuclear mobility of the pioneer transcription factor FoxA. Genes Dev. 2009, 23:804-809.
36. Wang D., et al. Reprogramming transcription by distinct classes of enhancers functionally defined by eRNA. Nature 2011, 474:390-394.
37. Eeckhoute J., et al. Cell-type selective chromatin remodeling defines the active subset of FOXA1-bound enhancers. Genome Res. 2009, 19:372-380.
38. Wang Q., et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009, 138:245-256.
39. Hoffman B.G., et al. Locus co-occupancy, nucleosome positioning, and H3K4me1 regulate the functionality of FOXA2-, HNF4A-, and PDX1-bound loci in islets and liver. Genome Res. 2010, 20:1037-1051.
40. He H.S.H.S., et al. Nucleosome dynamics define transcriptional enhancers. Nat. Genet. 2010, 42:343-347.
41. Barski A., et al. High-resolution profiling of histone methylations in the human genome. Cell 2007, 129:823-837.
42. Hurtado A., et al. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 2011, 43:27-42.
43. Fu Y.T., et al. The insulator binding protein CTCF positions 20 nucleosomes around its binding sites across the human genome. PLoS Genet. 2008, 4:e1000138.
44. Sabo P.J., et al. Genome-scale mapping of DNase I sensitivity in vivo using tiling DNA microarrays. Nat. Methods 2006, 3:511-518.
45. Boyle A.P., et al. High-resolution mapping and characterization of open chromatin across the genome. Cell 2008, 132:311-322.
46. Giresi P.G., et al. FAIRE (formaldehyde-assisted isolation of regulatory elements) isolates active regulatory elements from human chromatin. Genome Res. 2007, 17:877-885.
47. Razin S.V., et al. Chromatin domains and regulation of transcription. J. Mol. Biol. 2007, 369:597-607.
48. Winkler D.D., Luger K. The histone chaperone Fact: structural insights and mechanisms for nucleosome reorganization. J. Biol. Chem. 2011, 286:18369-18374.
49. Hargreaves D.C., Crabtree G.R. ATP-dependent chromatin remodeling: genetics, genomics and mechanisms. Cell Res. 2011, 21:396-420.
50. John S., et al. Chromatin accessibility pre-determines glucocorticoid receptor binding patterns. Nat. Genet. 2011, 43:264-268.
51. Wu J.I., et al. Understanding the words of chromatin regulation. Cell 2009, 136:200-206.
52. Krysinska H., et al. A two-step, PU.1-dependent mechanism for developmentally regulated chromatin remodeling and transcription of the c-fms gene. Mol. Cell. Biol. 2007, 27:878-887.
53. Zaret K.S. Regulatory phases of early liver development: paradigms of organogenesis. Nat. Rev. Genet. 2002, 3:499-512.
54. Yan J.Z., et al. The forkhead transcription factor FoxI1 remains bound to condensed mitotic chromosomes and stably remodels chromatin structure. Mol. Cell. Biol. 2006, 26:155-168.
55. Eeckhoute J., et al. Defining specificity of transcription factor regulatory activities. J. Cell Sci. 2009, 122:4027-4034.
56. Cuesta I., et al. The forkhead factor FoxE1 binds to the thyroperoxidase promoter during thyroid cell differentiation and modifies compacted chromatin structure. Mol. Cell. Biol. 2007, 27:7302-7314.
57. Hatta M., Cirillo L.A. Chromatin opening and stable perturbation of core histone:DNA contacts by FoxO1. J. Biol. Chem. 2007, 282:35583-35593.
58. Berkes C.A., et al. Pbx marks genes for activation by MyoD indicating a role for a homeodomain protein in establishing myogenic potential. Mol. Cell 2004, 14:465-477.
59. Holmes K.A., et al. Transducin-like enhancer protein 1 mediates estrogen receptor binding and transcriptional activity in breast cancer cells. Proc. Natl. Acad. Sci. U.S.A. 2011, 10.1073/pnas.1018863108.
60. Shoemaker J., et al. GATA-3 directly remodels the IL-10 locus independently of IL-4 in CD4+ T cells. J. Immunol. 2006, 176:3470-3479.
61. Li Z.Y., et al. The nucleosome map of the mammalian liver. Nat. Struct. Mol. Biol. 2011, 18:U742-U746.
62. Smale S.T. Pioneer factors in embryonic stem cells and differentiation. Curr. Opin. Genet. Dev. 2010, 20:519-526.
63. Tan S.K., et al. AP-2γ regulates estrogen receptor-mediated long-range chromatin interaction and gene transcription. EMBO J. 2011, 30:2569-2581.
64. Liber D., et al. Epigenetic priming of a pre-B cell-specific enhancer through binding of Sox2 and Foxd3 at the ESC stage. Cell Stem Cell 2010, 7:114-126.
65. Burda P., et al. The role of PU.1 and GATA-1 transcription factors during normal and leukemogenic hematopoiesis. Leukemia 2010, 24:1249-1257.
66. Sorlie T., et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:10869-10874.
67. Meissner A. Epigenetic modifications in pluripotent and differentiated cells. Nat. Biotechnol. 2010, 28:1079-1088.
68. Bernstein B.E., et al. A bivalent chromatin structure marks key developmental genes in embryonic stem cells. Cell 2006, 125:315-326.
69. Meissner A., et al. Genome-scale DNA methylation maps of pluripotent and differentiated cells. Nature 2008, 454:766-770.
70. Mikkelsen T.S., et al. Dissecting direct reprogramming through integrative genomic analysis. Nature 2008, 454:49-55.
71. Mueller B.U., et al. Heterozygous PU.1 mutations are associated with acute myeloid leukemia. Blood 2002, 100:998-1007.
72. Aspland S.E., et al. The role of E2A-PBX1 in leukemogenesis. Oncogene 2001, 20:5708-5717.
73. Xiao Y., et al. The lymphovascular embolus of inflammatory breast cancer exhibits a Notch 3 addiction. Oncogene 2011, 30:287-300.
74. Park J.T., et al. Identification of Pbx1, a potential oncogene, as a Notch3 target gene in ovarian cancer. Cancer Res. 2008, 68:8852-8860.
75. Kikugawa T., et al. PLZF regulates Pbx1 transcription and Pbx1-HoxC8 complex leads to androgen-independent prostate cancer proliferation. Prostate 2006, 66:1092-1099.
76. Gee J.M.W., et al. Overexpression of TFAP2C in invasive breast cancer correlates with a poorer response to anti-hormone therapy and reduced patient survival. J. Pathol. 2009, 217:32-41.
77. Friedrichs N., et al. Distinct spatial expression patterns of AP-2alpha and AP-2gamma in non-neoplastic human breast and breast cancer. Mod. Pathol. 2005, 18:431-438.
78. Williams C.M., et al. AP-2gamma promotes proliferation in breast tumour cells by direct repression of the CDKN1A gene. EMBO J. 2009, 28:3591-3601.
79. Badve S., et al. FOXA1 expression in breast cancer: correlation with luminal subtype A and survival. Clin. Cancer Res. 2007, 13:4415-4421.
80. Thorat M.A., et al. Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis. J. Clin. Pathol. 2008, 61:327-332.
81. Jain R.K., et al. High-level expression of forkhead-box protein A1 in metastatic prostate cancer. Histopathology 2011, 58:766-772.
82. Hu X., et al. Genetic alterations and oncogenic pathways associated with breast cancer subtypes. Mol. Cancer Res. 2009, 7:511-522.
83. Carroll J.S., et al. Genome-wide analysis of estrogen receptor binding sites. Nat. Genet. 2006, 38:1289-1297.
84. Nucera C., et al. FOXA1 is a potential oncogene in anaplastic thyroid carcinoma. Clin. Cancer Res. 2009, 15:3680-3689.
85. Jia L., et al. Functional enhancers at the gene-poor 8q24 cancer-linked locus. PLoS Genet. 2009, 5:e1000597.
86. Lu Y., et al. Functional annotation of risk loci identified through genome-wide association studies for prostate cancer. Prostate 2011, 71:955-963.
87. Siva N. 1000 Genomes project. Nat. Biotechnol. 2008, 26:256.
88. Hudson T.J., et al. International network of cancer genome projects. Nature 2010, 464:993-998.
89. Sahin M., et al. DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability. Cancer Metastasis Rev. 2010, 29:655-676.
90. Carafa V., et al. Histone deacetylase inhibitors: recent insights from basic to clinical knowledge & patenting of anti-cancer actions. Recent Patents Anti-Cancer Drug Discov. 2011, 6:131-145.
91. Tan J.H., et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J. Hematol. Oncol. 2010, 3:5.
92. Gronbaek K., et al. Epigenetic changes in cancer as potential targets for prophylaxis and maintenance therapy. Basic Clin. Pharmacol. Toxicol. 2008, 103:389-396.
93. Aikawa Y., et al. PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2. Nat. Med. 2010, 16:580-585.
94. Durual S., et al. Lentiviral PU.1 overexpression restores differentiation in myeloid leukemic blasts. Leukemia 2007, 21:1050-1059.
95. Sada E., et al. Vitamin K2 modulates differentiation and apoptosis of both myeloid and erythroid lineages. Blood 2010, 116:1627.
96. Nakshatri H., Badve S. FOXA1 as a therapeutic target for breast cancer. Expert Opin. Ther. Targets 2007, 11:507-514.
97. Moens C.B., Selleri L. Hox cofactors in vertebrate development. Dev. Biol. 2006, 291:193-206.
98. Morgan R., et al. Targeting HOX and PBX transcription factors in ovarian cancer. BMC Cancer 2010, 10:89.
99. Plowright L., et al. HOX transcription factors are potential therapeutic targets in non-small-cell lung cancer (targeting HOX genes in lung cancer). Br. J. Cancer 2009, 100:470-475.
100. Morgan R., et al. Antagonism of HOX/PBX dimer formation blocks the in vivo proliferation of melanoma. Cancer Res. 2007, 67:5806-5813.
101. Aulisa L., et al. Inhibition of cancer cell proliferation by designed peptide amphiphiles. Acta Biomaterialia 2009, 5:842-853.
102. Ademuyiwa F.O., et al. Expression of Forkhead-box protein A1, a marker of luminal A type breast cancer, parallels low oncotype DX 21-gene recurrence scores. Mod. Pathol. 2010, 23:270-275.
103. Yoon N.K., et al. Higher levels of GATA3 predict better survival in women with breast cancer. Hum. Pathol. 2010, 41:1794-1801.
104. Albajar M., et al. PU.1 expression is restored upon treatment of chronic myeloid leukemia patients. Cancer Lett. 2008, 270:328-336.
105. van Steensel B. Chromatin: constructing the big picture. EMBO J. 2011, 30:1885-1895.
106. Lee C.S., et al. The initiation of liver development is dependent on Foxa transcription factors. Nature 2005, 435:944-947.
107. Mcpherson C.E., et al. An active tissue-specific enhancer and bound transcription factors existing in a precisely positioned nucleosomal array. Cell 1993, 75:387-398.